Mitoxantrone and etoposide in patients with relapsed and refractory acute nonlymphocytic leukemia.
Rowe
J M
JM
Hematology Unit, University of Rochester Medical Center, NY.
Mazza
J J
JJ
Hines
J D
JD
Cassileth
P A
PA
Oken
M M
MM
Bennett
J M
JM
Andersen
J
J
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D004341:Drug Evaluation; D005047:Etoposide / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000401:mortality; D015479:Leukemia, Myelomonocytic, Acute / Q000188:drug therapy* / Q000401:mortality; D008942:Mitoxantrone / Q000008:administration & dosage / Q000009:adverse effects; D015337:Multicenter Studies as Topic; D012074:Remission Induction; D015996:Survival Rate; D014481:United States / Q000453:epidemiology
D005047:Etoposide; D008942:Mitoxantrone